Category: 69256-17-3

Inhibition of B virus (Macacine herpesvirus 1) by conventional and experimental antiviral compounds was written by Krug, P. W.; Schinazi, R. F.; Hilliard, J. K.. And the article was included in Antimicrobial Agents and Chemotherapy in 2009.Synthetic Route of C10H13FN2O5 The following contents are mentioned in the article:

B virus infection of humans results in high morbidity and mortality in as many as 80% of identified cases. The main objective of this study was to conduct a comparative anal. of conventional and exptl. antiviral drug susceptibilities of B virus isolates from multiple macaque species and zoonotically infected humans. We used a plaque reduction assay to establish the effective inhibitory doses of acyclovir, ganciclovir, and vidarabine, as well as those of a group of exptl. nucleoside analogs with known anti-herpes simplex virus activity. Four of the exptl. drugs tested were 10- to 100-fold more potent inhibitors of B virus replication than conventional antiviral agents. Drug efficacies were similar for multiple B virus isolates tested, with variations within 2-fold of the median effective concentration (EC50) for each drug, and each EC50 was considerably lower than those for B virus thymidine kinase (TK) mutants. We observed no differences in the viral TK amino acid sequence between B virus isolates from rhesus monkeys and those from human zoonoses. Differences in the TK protein sequence between cynomolgus and pigtail macaque B virus isolates did not affect drug sensitivity except in the case of one compound Taken together, these data suggest that future B virus zoonoses will respond consistently to conventional antiviral treatment. Further, the considerably higher potency of FEAU (2′-fluoro-5-ethyl-Ara-U) than of conventional antiviral drugs argues for its compassionate use in advanced human B virus infections. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Synthetic Route of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine is an aromatic heterocyclic organic compound similar to pyridine. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Synthetic Route of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Different antiviral potencies of BV-araU and related nucleoside analogs against herpes simplex virus type 1 in human cell lines and Vero cells was written by Machida, Haruhiko; Nishitani, Makiko; Suzutani, Tatsuo; Hayashi, Kozaburo. And the article was included in Microbiology and Immunology in 1991.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

Antiviral potencies against herpes simplex virus type 1 (HSV-1) of 1-β-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and 10 other nucleoside analogs in human embryonic lung fibroblast (HEL) cells were compared with those in Vero cells. 5-Halogenovinylarabinosyluracils, highly active in HEL cells, were inactive against all 3 laboratory-stocked strains of HSV-1 but exerted moderate antiviral effects on 3 clin. isolates in Vero cells. The reduction in anti-HSV-1 potencies of other representative nucleoside analogs in Vero cells was much less than those of 5-halogenovinylarabinosyluracils. However, significant antiviral potencies of BV-araU against laboratory strains were observed in other human and monkey fibroblast cells including an immortalized cell line. Significant enhancement of antiviral activity of BV-araU against a laboratory strain and a clin. isolate was demonstrated in Vero cells by the addition of 0.1 μM aminopterin or FUdR, an inhibitor of thymidylate synthesis. The potentiated anti-HSV-1 activity in Vero cells was comparable to the potency in HEL cells without the inhibitor. These results suggested that high activity of thymidylate synthesis and a large thymidylate pool size in Vero cells seem to be related to loss of anti-HSV-1 potency of BV-araU. Original tissue type, species, and the immortality may not be responsible for the reduced antiviral activity of BV-araU in Vero cells. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.Quality Control of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Mutagenic potential of anti-herpes agents was written by De Clercq, E.; Cassiman, J. J.. And the article was included in Life Sciences in 1986.SDS of cas: 69256-17-3 The following contents are mentioned in the article:

A number of anti-herpes agents which are either licensed for clin. use (acyclovir  [59277-89-3]) or subject of clin. studies (bromovinyldeoxyuridine  [82768-44-3], fluoroiodoaracytidine  [69123-90-6], dihydroxypropoxymethylguanine  [82410-32-0]) or under preclin. investigation (i.e., fluoroiodoarauridine  [69123-98-4]), fluoromethylarauridine  [69256-17-3], dihydroxybutylguanine  [83470-64-8], bromovinyldeoxycytidine  [84412-83-9], bromovinylarauridine  [77181-69-2], and carbocyclic bromovinyldeoxyuridine  [95463-56-2]) were evaluated for their ability to induce sister chromatid exchange (SCE), an indicator of mutagenesis. SCE was scored on metaphasic chromosomes of human lymphocytes which had been exposed to 5-bromo-2-deoxyuridine and varying concentrations of the test compounds The antiviral assays were based on the inhibition of the cytopathogenicity of herpes simplex virus for human diploid fibroblasts. Most compounds, i.e. acyclovir, bromovinyldeoxyuridine, or carbocyclic bromovinyldeoxyuridine, did either not induce SCE or only so at concentrations far above their min. antiviral concentrations However, fluoroiodoaracytidine and dihydroxypropoxymethylguanine affected the SCE rate at a concentration (≥ 4.5 μg/mL) that is readily achievable in blood following i.v. injection. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3SDS of cas: 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Pyrimidine derivatives also play an important role in drug development, either in concert with other compounds or on their own.SDS of cas: 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Effect of eight antiviral drugs on the reactivation of herpes simplex virus in explant cultures of latently infected mouse trigeminal ganglia was written by Klein, Richard J.; Friedman-Kien, Alvin E.. And the article was included in Journal of Investigative Dermatology in 1984.COA of Formula: C10H13FN2O5 The following contents are mentioned in the article:

The effect of several antiviral drugs on the reactivation of herpes simplex virus type 1 in explant cultures of latently infected mouse trigeminal ganglia was investigated. Phosphonoacetate  [4408-78-0] and phosphonoformate  [4428-95-9] which act directly on the virus-induced DNA polymerase, require a drug concentration of 400 μg/mL for the inhibition of virus reactivation in latently infected ganglia. Arabinosyladenine  [5536-17-4] and arabinosyladenine monophosphate  [29984-33-6], which are phosphorylated to triphosphates by cellular enzymes and inhibit virus synthesis either by blocking the DNA polymerase or by incorporation into viral DNA, require a concentration of only 100 μg/mL for the inhibition of the reactivation process. Drugs that are phosphorylated by the virus-induced thymidine kinase, such as acyclovir  [59277-89-3], arabinosylthymine  [605-23-2], bromovinyldeoxyuridine  [69304-47-8], and three fluorinated pyrimidine nucleosides require the lowest drug concentrations for complete inhibition of virus reactivation in latently infected ganglia explant cultures. These data suggest that the inhibition of virus reactivation is dependent not only on drug concentration, but also on the number of latently infected neurons in the ganglia. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3COA of Formula: C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.COA of Formula: C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Rapid Quantitative Determination of L-FMAU-TP from Human Peripheral-Blood Mononuclear Cells of Hepatitis B Virus-Infected Patients Treated with L-FMAU by Ion-Pairing, Reverse-Phase, Liquid Chromatography/Electrospray Tandem Mass Spectrometry was written by Lee, Jaeick; Yoo, Byung-Chul; Lee, Hyo-Suk; Yoo, Hee-Won; Yoo, Hye-Hyun; Kang, Min Jung; Kim, Dong-Hyun. And the article was included in Therapeutic Drug Monitoring in 2005.Application of 69256-17-3 The following contents are mentioned in the article:

The purpose of this study was to develop an anal. method for the determination of 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil triphosphate (L-FMAU-TP) in human peripheral blood mononuclear cells (PBMCs), and its application in the determination of cellular levels of L-FMAU-TP in PBMCs isolated from patients treated with 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil (L-FMAU). An ion-pairing liquid chromatog. (IPC) method, coupled with neg. ion electrospray ionization tandem mass spectrometry (ESI-MS/MS), was developed for the accurate and repeatable detection of L-FMAU-TP, with a limit of detection of 1.6 pmol/106 cells. The calibration curve for L-FMAU-TP was linear over the concentration range 1.6 to 80 pmol/106 cells. The intra- and inter-day precision was lower than 11.2%, and the accuracy was between 97.1 and 106.9%. When applied to the determination of L-FMAU-TP in PBMCs isolated from HBV-infected patients undergoing L-FMAU treatment, the levels reached a steady state concentration 4 wk after daily single oral administration of 20 mg L-FMAU, and these levels were maintained for up to 12 wk, but then decreased 12 wk after drug cessation. The terminal half-life of L-FMAU-TP in PBMCs after drug cessation was estimated to be 15.6 days. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Application of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Simultaneous determination of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry was written by Wiegand, Richard; Wu, Jianmei; Shields, Anthony F.; LoRusso, Patricia; Li, Jing. And the article was included in Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences in 2012.Computed Properties of C10H13FN2O5 The following contents are mentioned in the article:

A liquid chromatog. coupled with tandem mass spectrometry (LC-MS/MS) assay was developed and validated for simultaneous determination of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) uracil (FAU) and its active metabolite 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human blood plasma. FAU and FMAU were extracted from plasma samples using solid-phase extraction with Waters Sep-Pak Vac C18 cartridge. Chromatog. separation was achieved on a Waters Atlantis T3 C18 column with a gradient mobile phase consisting of MeOH and water with 0.45% formic acid (volume/volume) running at a flow rate of 0.2 mL/min. The analytes were monitored by triple quadrupole mass spectrometer under pos. ionization mode. The lower limit of quantitation (LLOQ) was 10 and 2 ng/mL for FAU and FMAU in plasma, resp. Calibration curves were linear over FAU and FMAU plasma concentration range of 10-2000 and 2-1000 ng/mL, resp. The intra-day and inter-day accuracy and precision were within the generally accepted criteria for bioanal. method (<15%). The method was successfully employed to characterize the plasma pharmacokinetics of FAU and FMAU in cancer patients receiving 1-h i.v. infusion of FAU 50 mg/m2. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Computed Properties of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Computed Properties of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Drug resistant and hypersensitive herpes simplex virus mutants: isolation and application to dissection of the pol locus was written by Coen, Donald M.; Chiou, Henry C.; Fleming, H. Edward Jr.; Leslie, Laurel K.; Retondo, Margaret J.. And the article was included in UCLA Symposia on Molecular and Cellular Biology, New Series in 1984.Category: pyrimidines The following contents are mentioned in the article:

Herpes simplex virus mutants resistant to antiviral drugs and aphidicolin are readily isolated in a single-step selection procedure. However, it was found that mutants resistant to one drug are often not substantially cross-resistant to others suggesting possible solutions to potential clin. resistance. Repeated plaque purification has proven essential for such analyses. Previous studies have identified PAA-, ACG-, and araA-resistance mutations in the DNA polymerase (pol) locus. Mutations conferring hypersensitivity to araA, PAA, FMAU, FIAU, BVdU, 2’NDG, and aphidicolin (Aph) were identified and several of these were mapped to the pol locus. The existence of either type of mutation in the pol locus implies that polymerase is a target for the drugs or otherwise mediates drug-sensitivity. Addnl., cross-resistance patterns of the mutants suggest that polymerases capable of discriminating against one nucleoside analog are incapable of discriminating against closely related compounds Mutations conferring altered sensitivity to the same drug map at different locations in the pol locus. Anal. of these mutations should aid in the functional dissection of the polymerase. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Category: pyrimidines).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.Category: pyrimidines

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase was written by Li, Jing; Kim, Seongho; Shields, Anthony F.; Douglas, Kirk A.; McHugh, Christopher I.; Lawhorn-Crews, Jawana M.; Wu, Jianmei; Mangner, Thomas J.; Lo Russo, Patricia M.. And the article was included in Journal of Clinical Pharmacology in 2016.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

FAU, a pyrimidine nucleotide analog, is a prodrug bioactivated by intracellular thymidylate synthase to form FMAU, which is incorporated into DNA, causing cell death. This study presents a model-based approach to integrating dynamic positron emission tomog. (PET) and conventional plasma pharmacokinetic studies to characterize the plasma and tissue pharmacokinetics of FAU and FMAU. Twelve cancer patients were enrolled into a phase 1 study, where conventional plasma pharmacokinetic evaluation of therapeutic FAU (50-1600 mg/m2) and dynamic PET assessment of 18F-FAU were performed. A parent-metabolite population pharmacokinetic model was developed to simultaneously fit PET-derived tissue data and conventional plasma pharmacokinetic data. The developed model enabled separation of PET-derived total tissue concentrations into the parent drug and metabolite components. The model provides quant., mechanistic insights into the bioactivation of FAU and retention of FMAU in normal and tumor tissues and has potential utility to predict tumor responsiveness to FAU treatment. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

In vitro and in vivo anti-HSV activities of 1-β-D-arabinofuranosyl-E-5-(2-halogenovinyl)uracil was written by Machida, Haruhiko; Sakata, Shinji; Kuninaka, Akira; Yoshino, Hiroshi. And the article was included in International Congress Series in 1982.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

E-5-(2-bromovinyl)arabinosyluracil (I) [77181-69-2] and E-5-(2-chlorovinyl)arabinosyluracil  [77181-70-5] were slightly more effective against herpes simplex virus-1 (HSV-1) infection, but much less effective against HSV-2 infection as compared to 5-vinylarabinosyluracil  [74886-33-2]. Thus, substitution of a H with a halogen at C-2 of the vinyl group increased the anti-HSV-1 activity of vinylarabinosyluracil but weakened its anti-HSV-2 activity. The anti-HSV-1 activity of I was almost equal to that of E-5-(2-bromovinyl)-2′-deoxyuridine BV-dUrd) [69304-47-8], 2′-fluoro-5-iodoarabinosylcytosine  [69123-90-6], and 2′-fluoro-5-methylarabinosyluracil  [69256-17-3]. I was less inhibitory to the growth of HEL-F cells than BV-dUrd. Thus, replacement of the deoxyribose moiety by arabinose in 5-vinyl and 5-halogenvinyl derivatives of 2′-deoxyuridines seems to weaken anticellular activity without significant loss of antiviral activity. The selectivity of I against HVS-1 was confirmed in terms of inhibition of DNA formation in HSV-1 infected cells. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Treatment of genital herpes simplex virus infections in guinea pigs was written by Kern, Earl R.. And the article was included in UCLA Symposia on Molecular and Cellular Biology, New Series in 1984.Application of 69256-17-3 The following contents are mentioned in the article:

Intravaginal inoculation of guinea pigs with herpes simplex virus type 2 provides an excellent model for genital herpes in humans. The infection is characterized by local viral replication in the vaginal tract followed by the appearance of vesicular lesions on external genital skin. After recovery from the primary infection, spontaneous recurrent lesions appear on the external genitalia. Oral treatment with acyclovir  [59277-89-3], 2′-deoxy-2′-fluoro-5-iodoarabinosylcytosin  [69123-90-6], 2′-fluoro-5-iodoarabinosyluracil  [69123-98-4], 2′-fluoro-5-methylarabinosyluracil  [69256-17-3], 9-(1,3-dihydroxy-2′-propoxymethyl)guanine  [82410-32-0], and i.m. treatment with recombinant human interferon-αA all reduced the severity of the primary infection. All compounds administered during recurrent disease also reduced the frequency of recurrent episodes, however, the frequency of recurrences returned to the level of controls when therapy was terminated. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Therapy for fungal infections is based mainly on four classes of antifungals: azoles, echinocandins, polyenes, and pyrimidine analogs.Application of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3